Literature DB >> 2699495

In vivo action of alpha-amylase inhibitor from cranberry bean (Phaseolus vulgaris) in rat small intestine.

M Kotaru1, K Iwami, H Y Yeh, F Ibuki.   

Abstract

An alpha-amylase inhibitor prepared from cranberry bean (Phaseolus vulgaris) was examined for its in vivo action on pancreatic alpha-amylase in rat small intestine. For this purpose, postprandial changes not only in intraluminal alpha-amylase activity but also in plasma glucose and insulin concentrations were measured at various times after administration of 2 g of 10% polyethylene glycol-containing experimental diets with and without the inhibitor. No considerable increase was observed in the levels of intraluminal alpha-amylase activity, blood sugar, and plasma insulin in the animals given the inhibitor at a dose of 10 mg each. These results suggest that the purified preparation from cranberry bean serves in fact as a potent inhibitor of rat pancreatic alpha-amylase.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2699495     DOI: 10.3177/jnsv.35.579

Source DB:  PubMed          Journal:  J Nutr Sci Vitaminol (Tokyo)        ISSN: 0301-4800            Impact factor:   2.000


  5 in total

1.  An in vitro and in vivo study of the α-amylase activity of phaseolamin.

Authors:  Neire Moura de Gouveia; Fernanda Vieira Alves; Fabiana Barcelos Furtado; Danielli Luana Scherer; Antonio Vicente Mundim; Foued Salmen Espindola
Journal:  J Med Food       Date:  2014-03-20       Impact factor: 2.786

2.  Trans-chalcone: a novel small molecule inhibitor of mammalian alpha-amylase.

Authors:  Mahmoud Najafian; Azadeh Ebrahim-Habibi; Nastaran Hezareh; Parichehreh Yaghmaei; Kazem Parivar; Bagher Larijani
Journal:  Mol Biol Rep       Date:  2010-09-21       Impact factor: 2.316

3.  The role of lipid and carbohydrate digestive enzyme inhibitors in the management of obesity: a review of current and emerging therapeutic agents.

Authors:  Sonia A Tucci; Emma J Boyland; Jason Cg Halford
Journal:  Diabetes Metab Syndr Obes       Date:  2010-05-10       Impact factor: 3.168

4.  Potential efficacy of preparations derived from Phaseolus vulgaris in the control of appetite, energy intake, and carbohydrate metabolism.

Authors:  Mauro Am Carai; Noemi Fantini; Barbara Loi; Giancarlo Colombo; Antonella Riva; Paolo Morazzoni
Journal:  Diabetes Metab Syndr Obes       Date:  2009-09-07       Impact factor: 3.168

5.  Heterologous expression of an α-amylase inhibitor from common bean (Phaseolus vulgaris) in Kluyveromyces lactis and Saccharomyces cerevisiae.

Authors:  Stephanie Brain-Isasi; Alejandro Álvarez-Lueje; Thomas Joseph V Higgins
Journal:  Microb Cell Fact       Date:  2017-06-15       Impact factor: 5.328

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.